Literature DB >> 22265272

Plasma osteoprotegerin level on admission is associated with no-reflow phenomenon after primary angioplasty and subsequent left ventricular remodeling in patients with acute ST-segment elevation myocardial infarction.

Ayhan Erkol1, Vecih Oduncu, Selçuk Pala, Filiz Kızılırmak, Alev Kılıcgedik, Fatih Yılmaz, Ahmet Güler, Can Yücel Karabay, Cevat Kırma.   

Abstract

OBJECTIVES: Osteoprotegerin (OPG) upregulates endothelial cell adhesion molecule response to TNF-α by upregulating angiopoietin-2 (Ang-2). The aim of this study was to investigate the association between admission plasma levels of OPG, Ang-2 and TNF-α in patients with acute ST-segment elevation myocardial infarction (STEMI) and no-reflow after primary angioplasty and subsequent left ventricular remodeling (LVR).
METHODS: Ninety-two patients with first STEMIs, reperfused within 12 h of symptom onset, were included. LVR was defined as a >20% increase in LV end-diastolic volume at 6-month follow-up assessed using echocardiography.
RESULTS: The incidences of angiographic no-reflow and electrocardiographic no-reflow were 40.2% and 55.4%, respectively. Thirty-six percent of patients subsequently developed LVR. OPG levels were significantly higher in patients who developed angiographic no-reflow (173 pg/ml, interquartile range [IQR] 83-416 vs 104 pg/ml, IQR 57-235; p=0.04), electrocardiographic no-reflow (160 pg/ml, IQR 81-315 vs 102 pg/ml, IQR 47-230; p=0.025) and LVR (174 pg/ml, IQR 120-342 vs 97 pg/ml, IQR 51-219; p=0.004). In multivariable logistic regression, OPG level was an independent predictor of angiographic (OR 1.05: 95% CI 1.01-1.08 [per 10 pg/ml increase]; p=0.005) and electrocardiographic (OR 1.04: 95% CI 1.00-1.07 [per 10 pg/ml increase]; p=0.04) no-reflow. ROC analysis showed an area under the curve of 0.69 for OPG and LVR. Plasma OPG≥132 pg/ml showed a sensitivity of 72% and a specificity of 61% for predicting LVR (OR 4.05: 95% CI 1.06-15.38; p=0.04).
CONCLUSION: High OPG level on admission is significantly associated with no-reflow after primary angioplasty and subsequent LVR at follow-up in patients with STEMI. Copyright Â
© 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22265272     DOI: 10.1016/j.atherosclerosis.2011.12.031

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes.

Authors:  Jay S Shavadia; Wendimagegn Alemayehu; Christopher deFilippi; Cynthia M Westerhout; Jasper Tromp; Christopher B Granger; Paul W Armstrong; Sean van Diepen
Journal:  J Thromb Thrombolysis       Date:  2021-10-27       Impact factor: 2.300

2.  Osteoprotegerin levels in ST-elevation myocardial infarction: Temporal profile and association with myocardial injury and left ventricular function.

Authors:  Christian Shetelig; Shanmuganathan Limalanathan; Jan Eritsland; Pavel Hoffmann; Ingebjørg Seljeflot; Jon Michael Gran; Pål Aukrust; Thor Ueland; Geir Øystein Andersen
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

3.  Serum Concentrations of Osteogenesis/Osteolysis-Related Factors and Micro-RNA Expression in ST-Elevation Myocardial Infarction.

Authors:  Tomasz Jadczyk; Tomasz Francuz; Wojciech Garczorz; Malgorzata Kimsa-Furdzik; Mieczyslaw Dutka; Ewa Gaik; Katarzyna Gruszczynska; Marcin Syzdol; Wojciech Wanha; Radoslaw Kurzelowski; Joanna Fluder; Zdenek Starek; Wojciech Wojakowski
Journal:  Cardiol Res Pract       Date:  2019-06-02       Impact factor: 1.866

Review 4.  Circulating biomarkers as predictors of left ventricular remodeling after myocardial infarction.

Authors:  Michał Węgiel; Tomasz Rakowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2021-03-27       Impact factor: 1.426

5.  Serum Osteoprotegerin Is an Independent Marker of Left Ventricular Hypertrophy, Systolic and Diastolic Dysfunction of the Left Ventricle and the Presence of Pericardial Fluid in Chronic Kidney Disease Patients.

Authors:  Katarzyna Romejko; Aleksandra Rymarz; Katarzyna Szamotulska; Zbigniew Bartoszewicz; Stanisław Niemczyk
Journal:  Nutrients       Date:  2022-07-14       Impact factor: 6.706

6.  Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention.

Authors:  Qinyao Zhang; Meirong Hu; Shumei Ma
Journal:  J Atheroscler Thromb       Date:  2021-02-05       Impact factor: 4.928

Review 7.  Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases.

Authors:  Mieczysław Dutka; Rafał Bobiński; Wojciech Wojakowski; Tomasz Francuz; Celina Pająk; Karolina Zimmer
Journal:  Heart Fail Rev       Date:  2021-07-27       Impact factor: 4.654

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.